15-PGDH inhibition protects in Parkinson's models
Analysis based on 7 articles · First reported Jul 06, 2026 · Last updated Jul 09, 2026
This research provides a rationale for repurposing 15-PGDH inhibitors for Parkinson's disease, potentially opening a new market for existing drugs. Companies developing such inhibitors may see increased interest from investors.
Researchers at University Hospitals Cleveland Medical Center, Case Western Reserve University, and the United States — Louis Stokes Cleveland VA Medical Center, co-led by Andrew A. Pieper and Sanford Markowitz, have shown that inhibiting the enzyme 15-PGDH protects against neurodegeneration in three mouse models of Parkinson's disease. The study, published in Redox Biology, found that both genetic and pharmacologic inhibition of 15-PGDH restored redox homeostasis, reducing neuroinflammation, neuronal cell death, and motor impairment. The 15-PGDH inhibitor SW033291 showed high CNS penetration, and the inhibitor MF-300 has completed Phase I clinical trials with no toxicity. The findings suggest that drugs already in development for other conditions could be repurposed for Parkinson's disease.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard